| DON'T BUY | 1.500 | Bill Carrigan | This could be a time when money moves back into the health care. Usually the small cap biotech stocks, such as Biovale (BVF-T), Patheon (PTI-T), MDS (MDS-T), etc. move together. Don't just buy one, buy 3 or 4 of them. This one is a pretty thin trader, so would stay away from it. | 2005-08-09 | |
| DON'T BUY | 1.750 | Peter Hodson | Consolidated stock at 4 to 1 to meet Nasdaq requirements. Markets hate reverse consolidations. Typically it's not a good sign as it means you've got too many shares outstanding. Not a great company, so wouldn't expect a whole lot from this company in the future. | 2005-06-13 | |
| VAGUE | 1.580 | Michael Sprung | Speculative future. | 2004-02-09 | |
| BUY | 1.620 | Andrew McCreath | It will expire again, company has run out of money many times. Take money out, while money is on the table. | 2004-01-28 | |
| SELL | 1.560 | Andrew McCreath | Basically, you are paying for an option. The company has run out of money many times and they continue to have regulatory problems with their product. | 2004-01-26 | |
| DON'T BUY | 1.580 | Gavin Graham | Built a nice plant in Mississauga, but found they had trouble with their blood substitute. Now a speculative stock. | 2003-12-15 | |
| DON'T BUY | 1.700 | Robert Floyd | Have made arrangements with another biotech company by contracting for part of their facility. Should be getting some revenues. Not a fan. | 2003-12-08 | |
| DON'T BUY | 1.700 | John Sinkins, CFA | A speculative play. Hemalink stalled in face two clinical trials. Build a plant. Limited visibility going forward. | 2003-12-08 | |
| DON'T BUY | 0.870 | Lou Schizas | Ran into trouble with their lead product. Down to about $900,000 in cash. The company is on life support. | 2003-09-05 | |
| DON'T BUY | 0.720 | John Sinkins, CFA | Very speculative. FDA trials didn't go well. | 2003-03-31 | |
| DON'T BUY | 0.620 | Glenn Paradis, BA, CFA | A lot of problems. May not survive. | 2003-03-17 | |
| DON'T BUY | 2.890 | David Baskin | A long way from being a mature company with mature products. Speculative. | 2003-01-14 | |
| DON'T BUY | 2.890 | Michael Smedley | Never seems to get it together. | 2003-01-14 | |
| DON'T BUY | 2.500 | John Zechner | Worst is behind them. Would prefer owning through MDS. | 2002-12-05 | |
| WEAK BUY | 1.900 | Bruce Campbell | OK for a long term hold. Buy on weakness. | 2002-11-07 | |
| DON'T BUY | 1.290 | Robert Floyd | Has some problems. Cash position is down to one year. If they issue stocks to rais cash, it will dilute these shares further. | 2002-11-01 | |
| DON'T BUY | 1.130 | Mike Weir | Very risky situation. May have to dilute stock by issuing more shares. | 2002-10-02 | |
| DON'T BUY | 0.850 | Gavin Graham | Could run out of cash. | 2002-09-20 | |
| DON'T BUY | 1.070 | Gavin Graham | Had delays in getting product out. A lot of cash. Risky unless you buy several small pharmaceuticals to spread the risk. | 2002-08-20 | |
| DON'T BUY | 1.030 | David Baskin | Has cash burn and has to raise money. Speculative. | 2002-08-19 | |
| DON'T BUY | 3.750 | Bruce Cooper | Have had a tough time getting approval. Competition is growing. Future is uncertain. | 2002-05-02 | |
| DON'T BUY | 3.900 | Michael Smedley | Hard to like. | 2002-04-29 | |
| DON'T BUY | 4.000 | Robert Floyd | Disappointed with their product results. High burn rate. | 2002-04-25 | |
| DON'T BUY | 4.600 | Glenn Paradis, BA, CFA | Has disappointed. Not convinced about the needs for blood substitute. | 2002-04-18 | |
| DON'T BUY | 4.580 | David Driscoll | Treat as a trading stock. No value right now. | 2002-04-03 | |
| DON'T BUY | 4.620 | Joe Connolly | Only has one drug. Needds more diversification. | 2002-04-02 | |
| DON'T BUY | 4.200 | Bruce Cooper | Approval of Hemolink was denied. No revenues or earnings. | 2002-03-21 | |
| DON'T BUY | 4.200 | Joe Connolly | Too much competition. | 2002-03-21 | |
| BUY | 5.880 | Rob Callander | At a good price and a good buy for an aggressive investor. | 2002-03-20 | |
| DON'T BUY | 6.290 | David Baskin | A one trick pony. Speculative. | 2002-02-19 | |
| DON'T BUY | 7.450 | Mike Weir | Have ahd difficulties in their trials. May have a weak cash position. | 2002-01-23 | |
| DON'T BUY | 9.000 | David Driscoll | Starting to move up, but prefers to wait for the product to start selling. | 2002-01-09 | |
| BUY | 7.350 | Malvin Spooner | A long term situation, but expects it will do OK. | 2001-12-31 | |
| BUY | 7.490 | Brian Acker, CA | Sees it going up. Use a $6.90 stop loss. Expects it to get to $8.75 at which time it should be looked at again. | 2001-12-28 | |
| WAIT | 7.400 | Robert Floyd | A lot of competition in blood substitutes. | 2001-12-21 | |
| DON'T BUY | 5.900 | Brian Acker, CA | Prefers other companies that have earnings. Might buy at $3. | 2001-12-06 | |
| DON'T BUY | 6.020 | Joe Connolly | Wait for FDA approval. | 2001-11-28 | |
| DON'T BUY | 6.250 | John Zechner | If you own, hold. | 2001-11-27 | |
| DON'T BUY | 6.400 | Fred Ketchen | Watch how the trials go. | 2001-11-26 | |
| WEAK BUY | 6.500 | Robert Floyd | Analysts are expecting a large upside. Will take time to get through the FDA phases. | 2001-11-22 | |
| DON'T BUY | 4.800 | David Driscoll | Wait for FDA approval to go through. Will be a good product. | 2001-11-05 | |
| BUY | 6.450 | Brendan Caldwell | A worthwhile stock to own a little bit. At a good price. | 2001-10-25 | |
| WEAK BUY | 5.980 | Richard Stone | Good product. Phase 3is delayed for a year. Lots of competition, but room for all. Speculative. | 2001-10-11 | |
| DON'T BUY | 4.470 | Fred Ketchen | Will take a while for the product to come on stream. Has strong competition. | 2001-09-07 | |
| DON'T BUY | 4.700 | Ian Nakamoto | High valuation and delay on trials was a downer. | 2001-09-05 | |
| DON'T BUY | 5.050 | Richard Stone | Phase 3 stage required restructuring so competitors now have a year's head start. | 2001-09-04 | |
| DON'T BUY | 5.460 | David Baskin | Biotechs can have a drop if the core product doesn't work out. Speculative. | 2001-08-31 | |
| WEAK BUY | 6.350 | Gavin Graham | Will be 6/9 months before getting approval. Good price. | 2001-08-24 | |
| DON'T BUY | 7.200 | Mark Jackson, CFA | Not sure there will be the demand for a blood substitute. Can/will clients change their systems to accommodate? | 2001-08-16 | |
| BUY | 7.350 | Gavin Graham | FDA has delayed. Expect them to back on track in 6/9 months. Good price. | 2001-08-15 | |
| HOLD | 6.600 | Robert Floyd | FDA knocked them back. Look for signs that they are getting back to basics and they revise their applications. | 2001-08-14 | |
| BUY | 11.500 | Brendan Caldwell | Still waiting to get approval. Should be good. | 2001-08-03 | |
| DON'T BUY | 12.320 | Bruce Cooper | Should get product approved, but not sure that demand will be strong. Also has competition. | 2001-08-01 | |
| HOLD | 13.200 | David Driscoll | Having problems getting distribution/approvals. | 2001-06-22 | |
| DON'T BUY | 14.950 | Bruce Cooper | Will be a market for the product, but has competition and not sure how big the market will be. | 2001-06-07 | |
| DON'T BUY | 14.850 | John Sinkins, CFA | Preliminary approval in Canada & Europe and in final phase in US. Expensive treatment. Covered by government/health ins. ? | 2001-06-06 | |
| DON'T BUY | 15.900 | John Zechner | Better to own it through MDS | 2001-05-25 | |
| DON'T BUY | 16.150 | David Driscoll | Good products in final phase, but a one trick pony. | 2001-05-24 | |
| BUY | 14.000 | Ed Ho | Still waiting approval. Once that happens, stock should move up. | 2001-04-18 | |
| STRONG BUY | 14.350 | Pier Donnini | Got US financing. Getting US attention now (analyst has $18US) Look for new partner announcements in Europe. | 2001-03-27 | |
| BUY | 14.950 | Ed Ho | Almost at the commercial stage | 2001-03-19 | |
| BUY | 13.750 | Robert Floyd | Good concept. Could have competition down the road, but a good company. | 2001-03-15 | |
| WAIT | 14.300 | Bruce Cooper | Will probably get approved. Not sure how commercially viable it is. | 2001-03-08 | |
| TOP PICK | 13.760 | Pier Donnini | Just got on NASDAQ. With exposure in US, just got some good financing. Should double | 2001-03-06 | |
| DON'T BUY | 13.630 | Michael Lee-Chin | Stock price has just dropped. Still a venture company and they don't invest unless there is cash flow. | 2001-03-01 | |
| DON'T BUY | 13.630 | John Zechner | Recently got new financing. Good company. No revenues yet. Prefers buying this via MDS | 2001-03-01 | |
| BUY | 15.990 | Brendan Caldwell | Expects it to be the leader in blood substitutes. | 2001-02-26 | |
| BUY | 15.700 | Richard Stone | In phase 3. Expects it to be successful. Good mngmnt. Volatile. Play it through MDS. | 2001-02-23 | |
| BUY | 18.100 | Ray Steele | Going up. May be because of the new exposure to US on NASDAQ | 2001-02-14 | |
| BUY | 18.200 | Pierre Bernard | Now moving because of increased exposure to the US market through their NASDQ listing | 2001-02-13 | |
| BUY | 16.000 | Malvin Spooner | Likes this stock. Everything is in place for manufacturing so expects revenues to start. Volatile | 2001-01-31 | |
| BUY | 15.300 | Brendan Caldwell | Has an outstanding product. Long term should be good, but prefers to play this through MDS | 2001-01-26 | |
| TOP PICK | 14.500 | Pier Donnini | Had a rough time because of rumors on competition problems. Good company. Dramatically undervalued. Will go much higher when US investors see it | 2001-01-19 | |
| WATCH | 12.750 | Steven Misener | Very attractive product. A lot of competition | 2001-01-02 | |
| BUY | 14.750 | Ed Ho | Just got some major financing. A big step | 2000-12-11 | |
| DON'T BUY | 14.500 | Richard Stone | Prefers playing this through MDS | 2000-12-01 | |
| BUY on WEAKNESS | 15.000 | Malvin Spooner | Great company/product Most approvals done. Starting mass production | 2000-11-24 | |
| BUY | 15.000 | Malvin Spooner | Hasn't moved, but have patience. Getting ready for sales | 2000-10-24 | |
Experts that have talked about Hemosol
Rss Top Picks Feed
